Centralized databases, reduced competition for patients, and higher starting doses are among some of the benefits to conducting research in Poland, which ranks seventh in Europe for clinical trial participation, says Moleculin CEO.
China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.
The discussion surrounding clinical trial awareness has evolved “from mere conversations to action, creativity, and inclusivity from multiple stakeholders,” and will continue to evolve as we work together to create a paradigm shift in awareness, says...
The industry in March saw new c-suite appointments at CRF Bracket, PCI Pharma Services, George Clinical, and Paragon Bioservices – as well as moves to boost medical device and DMPK services at Premier Research and Sygnature Discovery, respectively.
Clinical trials in the UK are reportedly declining as the country grapples with Brexit – a change which could make access to preclinical and bioanalytical research materials, including NHPs, problematic, says QPS.
The FDA is addressing increasingly complex eligibility criteria in an effort to expand patient participation in cancer clinical trials, a move which will help shorten study recruitment timelines, among several other benefits to both researchers and patients,...
CRF Bracket closes its first full quarter as a combined entity with more than a 20% increase in new clinical trial business – and will “aggressively look for partners” from its current and future customers, says CEO.
Datathon participants identify five repurposable drug candidates, applying AI to identify genes of interest and support target identification – a task that previously would have taken years, says industry expert.